BeStock  
Stocks › Biotechnology › ZVRA

Zevra Therapeutics ZVRA

US equityMarket cap rank #3557Biotechnology
$11.08 +$0.35 (+3.26%)
Pre-market · Oct 8, 7:00 am ET · After hours $11.19 +0.99%
Open$10.68
Prev close$10.73
Day range$10.57 – $11.38
Volume936.5K
Market cap$657.97M
P/E (TTM)11.9
Dividend yield–

Earnings

Average move on report day±8.0%last 16 reports
Closed higher6 of 1638% of the time
Best reaction+21.3%
Worst reaction-19.8%

Stock move on the day after each report

-3.5%2023/Q3-11.0%2023/Q4-0.3%2024/Q1-0.4%2024/Q2+1.1%2024/Q3-1.9%2024/Q4+3.4%2025/Q1-19.8%2025/Q2-9.7%2025/Q3+21.3%2025/Q4-2.2%2026/Q1+12.8%2026/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q25 Aug 2026After Market±11.8%+12.82%Bigger than priced
2026/Q16 May 2026After Market±13.2%-2.22%Within range
2025/Q49 Mar 2026After Market±20.0%+21.27%Bigger than priced
2025/Q35 Nov 2025After Market±14.0%-9.73%Within range
2025/Q212 Aug 2025After Market±16.9%-19.81%Bigger than priced
2025/Q113 May 2025After Market±21.7%+3.43%Within range
2024/Q411 Mar 2025After Market±17.2%-1.86%Within range
2024/Q312 Nov 2024After Market±14.1%+1.05%Within range
2024/Q213 Aug 2024None±26.6%-0.44%Within range
2024/Q18 May 2024Pre Market±33.3%-0.29%Within range
2023/Q428 Mar 2024After Market±21.7%-11.03%Within range
2023/Q37 Nov 2023Pre Market±14.3%-3.51%Within range
2023/Q214 Aug 2023Pre Market±26.3%+3.85%Within range
2023/Q115 May 2023Pre Market±29.4%+3.07%Within range
2022/Q47 Mar 2023Pre Market±26.4%-19.44%Within range
2022/Q39 Nov 2022After Market–-13.99%–

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: Q2, ended Jun 2026

Revenue$39.66M+53.3% YoY
Operating profit$16.78M+236.1% YoY
Net profit$8.75M-88.3% YoY
Diluted EPS$0.14-88.4% YoY
Free cash flow$16.82M+540.9% YoY
Operating cash flow$17.03M

Revenue, last 8 quarters

$3.7MSep '24$12.0MDec '24$20.4MMar '25$25.9MJun '25$26.1MSep '25$34.1MDec '25$36.2MMar '26$39.7MJun '26

Net profit, last 8 quarters

$-33.2MSep '24$-35.7MDec '24$-3.1MMar '25$74.7MJun '25$-544.0KSep '25$12.2MDec '25$37.9MMar '26$8.8MJun '26

Profitability & balance sheet

Gross margin95.5%
Operating margin28.7%
Net margin42.8%
Return on equity34.8%
Return on assets20.8%
Return on invested capital27.3%
Current ratio5.17
Liabilities / assets28.1%
Cash & investments$221.57M
Total debt$870,000.00
Net cash (debt)$220.70M
Free cash flow / sales24.0%

Discussion

No comments yet — be the first to weigh in on ZVRA.

Leave a comment

Scroll to Top